
FDA approves new drug for schizophrenia related agitation
The Food and Drug Administration (FDA) has approved biopharmaceutical company BioXcel Therapeutics’ acute treatment for schizophrenia or bipolar disorder-associated agitation. BioXcel Therapeutics’ IGALMI (dexmedetomidine) is the first new treatment for schizophrenia or bipolar disorder-associated agitation in almost 10 years, according to the company. The FDA’s… Read More






